<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01806376</url>
  </required_header>
  <id_info>
    <org_study_id>SBYN-Ⅰ-01</org_study_id>
    <nct_id>NCT01806376</nct_id>
  </id_info>
  <brief_title>A Phase I Study of Subutinib Maleate Capsules on Toleration and Pharmacokinetics</brief_title>
  <official_title>A Phase I Study of Subutinib Maleate Capsules on Toleration and Pharmacokinetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. purpose: to explore the maximum tolerated dose, dose-limiting toxicity of oral Subutinib&#xD;
           Maleate capsules and rational dosage regimen for phase Ⅱ study&#xD;
&#xD;
        2. Experimental Design： A phase Ⅰ study of single-center&#xD;
&#xD;
        3. Test drug: Subutinib Maleate capsules&#xD;
&#xD;
        4. Sample size≥20&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to explore the maximum tolerated dose, dose-limiting&#xD;
      toxicity of oral Subutinib Maleate capsules and rational dosage regimen for phase Ⅱ study, to&#xD;
      investigate the pharmacokinetics of single and multiple oral doses of Subutinib Maleate&#xD;
      capsules.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity， maximum tolerated dose.</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>2 months</time_frame>
    <description>Subutinib Maleate pharmacokinetic parameters , include AUC, Cmax, Tmax, and t1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>2 months</time_frame>
    <description>The response of Subutinib Maleate on tumor.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Subutinib Maleate capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation will be dependent on any dose limiting toxicities</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subutinib Maleate capsules</intervention_name>
    <description>Dose escalation will be dependent on any dose limiting toxicities</description>
    <arm_group_label>Subutinib Maleate capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who have histologically or cytologically confirmed solid tumors&#xD;
&#xD;
          -  Subjects who have failed standard effective therapy or have a diagnosis for which no&#xD;
             standard effective treatment is available;&#xD;
&#xD;
          -  Aged 18 to 70 years old; Eastern Cooperative Oncology Group (ECOG) performance status&#xD;
             (PS) 0-2; Life expectancy greater than 3 months;&#xD;
&#xD;
          -  If the subject has been given other chemotherapy drugs, it's necessary to discontinue&#xD;
             them more than 4 weeks. If the chemotherapy drugs are Nitrosoureas and Mitomycin C,&#xD;
             it's necessary to discontinue them more than 6 weeks. If the subject has accepted&#xD;
             major surgery, it's necessary to wait more than 4 weeks before the subject&#xD;
             participating in this study.&#xD;
&#xD;
          -  Blood test: Hb≥100g/L(no blood transfusion within 14 days); ANC≥1.5×109/L,&#xD;
             PLT≥100×109/L&#xD;
&#xD;
          -  Biochemistry: TBIL and ALT and AST and Cr are in normal range, or creatinine clearance&#xD;
             ≥60ml/min; Triglyceride≤3.0mmol/L; Cholesterol ≤7.75mmol/L.&#xD;
&#xD;
          -  Doppler ultrasound measurement: LVEF ≥ LLN&#xD;
&#xD;
          -  Female subjects should agree to take contraceptives during the study and within 6&#xD;
             months after the study (such as intrauterine device [IUD], contraceptive drugs or&#xD;
             condoms); within 7 days before they enter the study, their serum or human chorionic&#xD;
             gonadotropin should be negative, and must be in the non-lactation period; male&#xD;
             subjects should agree to take contraceptives during the study and within 6 months&#xD;
             after the study.&#xD;
&#xD;
          -  The subject is willing to participate in this study, and he/she has signed the&#xD;
             Informed Consent Form, with good compliance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject has participated in other drug clinical research in the past 4 weeks.&#xD;
&#xD;
          -  The subject is accompanied with several factors which will influence the&#xD;
             investigational drug administration orally, such as inability to swallow or after&#xD;
             gastrointestinal resection or chronic diarrhea or intestinal obstruction.&#xD;
&#xD;
          -  Central nervous system metastasis definitely.&#xD;
&#xD;
          -  The subject is suffering from hypertension or myocardial ischemia or myocardial&#xD;
             infarction or arrhythmia (including QT interval≥440ms) or Grade I heart failure.&#xD;
&#xD;
          -  If the subject's systolic BP is over 140mmhg, with diastolic BP over 90mmhg, or the&#xD;
             subject's blood pressure is well-controlled, he/she is not permitted to enroll in this&#xD;
             study as well.&#xD;
&#xD;
          -  The subject's urinalysis displays that urinary protein ≥ ++ , combined with 24-hour&#xD;
             urinary protein &gt; 1.0g.&#xD;
&#xD;
          -  The subject's is suffering from wounds or fractures which can not be cured for long&#xD;
             time.&#xD;
&#xD;
          -  Abnormal coagulation: The subject has bleeding tendency such as active peptic ulcer or&#xD;
             the subject is receiving thrombolytic or anticoagulant therapy.&#xD;
&#xD;
          -  There are pre-dosing arterial/venous thrombotic events on this subject, such as&#xD;
             cerebrovascular accident (including TIA) or deep vein thrombosis or pulmonary&#xD;
             embolism.&#xD;
&#xD;
          -  The subject is accepting anticoagulants or vitamin K antagonists such as warfarin or&#xD;
             heparin or analogue therapy; If the subject's INR ≤ 1.5, he/she is allowed to use&#xD;
             small doses of warfarin (1mg oral q d) or small doses of aspirin(less than 100mg each&#xD;
             day), and the purpose of the treatment should be prevention.&#xD;
&#xD;
          -  Abnormal thyroid function.&#xD;
&#xD;
          -  There is history of mental drug abuse occurred in the subject, or the subject is&#xD;
             suffering from mental disorders.&#xD;
&#xD;
          -  There is history of immunodeficiency occurred in the subject, including HIV positive&#xD;
             or other acquired or congenital immunodeficiency diseases, or the subject has accepted&#xD;
             organ transplant before.&#xD;
&#xD;
          -  Lung squamous cell carcinoma.&#xD;
&#xD;
          -  The subject has received small molecule targeted drug therapy of inhibition of VEGFR-2&#xD;
             and PDGFRβ&#xD;
&#xD;
          -  According to the investigator's judgment, there are concomitant diseases which will&#xD;
             seriously do harm to the subject's safety or obstruct the subject to complete the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li jin, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cao j nin, doctor</last_name>
      <phone>02164175590</phone>
      <phone_ext>8216</phone_ext>
      <email>cao_junning@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>March 1, 2013</study_first_submitted>
  <study_first_submitted_qc>March 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2013</study_first_posted>
  <last_update_submitted>March 7, 2013</last_update_submitted>
  <last_update_submitted_qc>March 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maleic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

